Stocktoria

Sensus Healthcare, Inc. SRTS

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2016-06-03 · LEI

Sensus Healthcare, Inc. (SRTS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $27.5M at a -28.1% net margin.

Chart by TradingView
41/100
Stocktoria Quality Score · grade D
4/9
Piotroski F — financial health
14.36
Altman Z″ — distress risk · safe
Dividend yield · no dividend
-3.64
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
3 4 2 2 1 5 4 3 4 4 2016201720182019202020212022202320242025
Altman Z″
7.43 2.93 7.46 6.48 3.68 8.58 13.21 16.43 16.19 14.36 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$3.13 as of 2026-08-01 · -7.7% 1y
$2.91$5.1352-wk

Beneish M-score: -3.64 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$50M
Net margin 5y avg11.9%
Return on equity 5y avg12.6%
Beta1.09
Employees60

Analyst price target

$5.75 +83.7% vs last
· 4 analysts
target range $4.50 – $6.50

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net bought +$163,562 on the open market · 8 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 45%
Net marginstronger than 33%
Return on equitystronger than 45%
Revenue growthstronger than 6%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 4/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.776
Retained earnings / assets0.108
EBIT / assets-0.194
Equity / liabilities9.734

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
SRTSSensus Healthcare, Inc.4/914.36-34.3%
SSKNSTRATA Skin Sciences, Inc.4/9-8.5%
BDMDBaird Medical Investment Holdings Ltd1/90.49-39.2%
DRIODarioHealth Corp.3/9-12.4-17.3%
OBIOOrchestra BioMed Holdings, Inc.5/9-7.02
MDAISpectral AI, Inc.3/9-11.78-33.6%
SNOASonoma Pharmaceuticals, Inc.2/9+36.7%

All Manufacturing companies →

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.

FAQ

Is SRTS financially healthy?

Sensus Healthcare, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does SRTS pay a dividend?

No, Sensus Healthcare, Inc. does not currently pay a dividend.

How profitable is SRTS?

In FY2025, Sensus Healthcare, Inc. had a net margin of -28.1% and a return on equity of -16.0%.

Is SRTS overvalued or undervalued?

Sensus Healthcare, Inc. trades at about 7.6× trailing earnings — below its 10-year norm (10-year range 6.3×–108.3×, median 30.8×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for SRTS?

The average Wall-Street price target for Sensus Healthcare, Inc. is $5.75, about 83.7% above the recent price, from 4 analysts.

Is SRTS a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Sensus Healthcare, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.